title: Recommendations for the optimal management of early and advanced urothelial carcinoma.
abstract: The field of urothelial carcinoma has shown considerable advances in terms of diagnosis, staging, and treatment. The increasing knowledge of molecular pathways and genes involved in the occurrence of this tumor has encouraged the search for new, more effective and less toxic therapies, and has prompted the design and development of clinical trials. However, the speed at which results are published makes it difficult for clinicians to cover the vast amount of information available. Moreover, in clinical practice some gaps remain concerning treatment options for patients who have progressed after first-line cisplatin-based combinations, who cannot tolerate cisplatin-based chemotherapy, or who have received platinum-based neoadjuvant or adjuvant therapy, and thus cannot be offered this option on disease progression. The purpose of this review is to issue a series of recommendations on the optimal management of early and advanced urothelial carcinoma based on current evidence and the available updated guidelines.
authors: Medical Oncology Department, Hospital Universitario 12 de Octubre, Avda. De Córdoba, S/N. 28041 Madrid, Spain. cdanicas@hotmail.com
authors: Daniel
authors: D
authors: Castellano
authors: Joan
authors: J
authors: Carles
authors: Emilio
authors: E
authors: Esteban
authors: José Manuel
authors: JM
authors: Trigo
authors: Miguel Ángel
authors: MÁ
authors: Climent
authors: José Pablo
authors: JP
authors: Maroto
authors: Xavier García
authors: XG
authors: del Muro
authors: Albert
authors: A
authors: Font
authors: Luis
authors: L
authors: Paz-Ares
authors: José Ángel
authors: JÁ
authors: Arranz
authors: Joaquim
authors: J
authors: Bellmunt
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D009154:Mutation; D020360:Neoadjuvant Therapy; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents